Nelipepimut-S may prevent recurrence in triple-negative breast cancer
The concurrent use of nelipepimut-S, a vaccine designed to stimulate CD8 T cells, in trastuzumab-treated patients with breast cancer and low HER2 expression is safe and does not contribute to excess toxicity, as well as prolongs disease-free survival specifically in those with triple-negative breast cancer, as shown in the results of a phase II trial.
